(Total Views: 389)
Posted On: 10/08/2024 7:59:08 AM
Post# of 148863
So if TAS is knocking out neutrophils while leronlimab depends on those neutrophils to eradicate the tumor, it sounds like the combination of leronlimab with TAS could in some way hamper or mitigate the effects of combining leronlimab to TAS.
What if the reverse is true? What are the chances of leronlimab mitigating the effects of TAS weakening the bone marrow/stem cells and neutrophils?
Why do you think there is less killing of the neutrophils when bevacizumab is added to TAS as you've stated?
What if the reverse is true? What are the chances of leronlimab mitigating the effects of TAS weakening the bone marrow/stem cells and neutrophils?
Why do you think there is less killing of the neutrophils when bevacizumab is added to TAS as you've stated?
(1)
(0)Scroll down for more posts ▼
